-
2
-
-
84860351786
-
Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database
-
Hemophilia Treatment Center Network (HTCN) Investigators
-
Carpenter SL, Michael Soucie J, Sterner S et al.; Hemophilia Treatment Center Network (HTCN) Investigators. Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia 2012; 18: e260-5.
-
(2012)
Haemophilia
, vol.18
, pp. e260-e265
-
-
Carpenter, S.L.1
Michael Soucie, J.2
Sterner, S.3
-
3
-
-
0033814048
-
Transfusion transmitted diseases in haemophilics from western India
-
Ghosh K, Joshi SH, Shetty S et al. Transfusion transmitted diseases in haemophilics from western India. Indian J Med Res 2000; 112: 61-4.
-
(2000)
Indian J Med Res
, vol.112
, pp. 61-64
-
-
Ghosh, K.1
Joshi, S.H.2
Shetty, S.3
-
4
-
-
34447250771
-
Disability in Indian patients with haemophilia
-
Kar A, Mirkazemi R, Singh P et al. Disability in Indian patients with haemophilia. Haemophilia 2007; 134: 398-404.
-
(2007)
Haemophilia
, vol.134
, pp. 398-404
-
-
Kar, A.1
Mirkazemi, R.2
Singh, P.3
-
5
-
-
84898028710
-
Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
-
Coyle TE, Reding MT, Lin JC et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12: 488-96.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 488-496
-
-
Coyle, T.E.1
Reding, M.T.2
Lin, J.C.3
-
6
-
-
84857627016
-
PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice
-
Peng A, Kosloski MP, Nakamura G et al. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. AAPS J 2012; 14: 35-42.
-
(2012)
AAPS J
, vol.14
, pp. 35-42
-
-
Peng, A.1
Kosloski, M.P.2
Nakamura, G.3
-
7
-
-
84873625664
-
BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation
-
Turecek PL, Bossard MJ, Graninger M et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32: S29-38.
-
(2012)
Hamostaseologie
, vol.32
, pp. S29-S38
-
-
Turecek, P.L.1
Bossard, M.J.2
Graninger, M.3
-
8
-
-
84916232822
-
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study
-
Powell JS, Apte S, Chambost H et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol 2014. doi:10.1111/bjh.13112.
-
(2014)
Br J Haematol
-
-
Powell, J.S.1
Apte, S.2
Chambost, H.3
-
9
-
-
84893606658
-
Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
-
Zollner S, Schuermann D, Raquet E et al. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014; 12: 220-8.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 220-228
-
-
Zollner, S.1
Schuermann, D.2
Raquet, E.3
-
10
-
-
84879460451
-
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo
-
Tang L, Leong L, Sim D et al. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. Haemophilia 2013; 19: 539-45.
-
(2013)
Haemophilia
, vol.19
, pp. 539-545
-
-
Tang, L.1
Leong, L.2
Sim, D.3
-
11
-
-
13244262642
-
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
-
Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1700-1708
-
-
Aledort, L.M.1
-
12
-
-
0345627213
-
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN)
-
van't Veer C, Golden NJ, Kalafatis M et al. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood 1997; 90: 3067-72.
-
(1997)
Blood
, vol.90
, pp. 3067-3072
-
-
van't Veer, C.1
Golden, N.J.2
Kalafatis, M.3
-
13
-
-
34447314172
-
Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients
-
Shetty S, Vora S, Kulkarni B et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007; 138: 541-4.
-
(2007)
Br J Haematol
, vol.138
, pp. 541-544
-
-
Shetty, S.1
Vora, S.2
Kulkarni, B.3
-
14
-
-
48249155867
-
Reduced clinical severity in a mutationally well-characterized cohort of severe hemophilia with associated thrombophilia
-
Shetty S, Ghosh K. Reduced clinical severity in a mutationally well-characterized cohort of severe hemophilia with associated thrombophilia. Am J Clin Pathol 2008; 130: 84-7.
-
(2008)
Am J Clin Pathol
, vol.130
, pp. 84-87
-
-
Shetty, S.1
Ghosh, K.2
-
15
-
-
34548791196
-
Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children - results of a multicenter studies
-
Kurnik K, Kreuz W, Horneff S et al. Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children - results of a multicenter studies. Haematologica 2007; 92: 982-5.
-
(2007)
Haematologica
, vol.92
, pp. 982-985
-
-
Kurnik, K.1
Kreuz, W.2
Horneff, S.3
-
16
-
-
84859718853
-
Protein C anticoagulant system - anti-inflammatory effects
-
Esmon CT. Protein C anticoagulant system - anti-inflammatory effects. Semin Immunopathol 2012; 34: 127-32.
-
(2012)
Semin Immunopathol
, vol.34
, pp. 127-132
-
-
Esmon, C.T.1
-
17
-
-
79955159111
-
Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, and ERK1/2 MAP kinases
-
Guitton C, Cottereau A, Gérard N et al. Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, and ERK1/2 MAP kinases. Am J Physiol Cell Physiol 2011; 300: C833-42.
-
(2011)
Am J Physiol Cell Physiol
, vol.300
, pp. C833-C842
-
-
Guitton, C.1
Cottereau, A.2
Gérard, N.3
-
18
-
-
0027438386
-
Interaction of activated protein C with serpins
-
Hermans JM, Stone SR. Interaction of activated protein C with serpins. Biochem J 1993; 295: 239-45.
-
(1993)
Biochem J
, vol.295
, pp. 239-245
-
-
Hermans, J.M.1
Stone, S.R.2
-
19
-
-
0036507774
-
Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma
-
Cvirn G, Gallistl S, Koestenberger M et al. Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res 2002; 105: 433-9.
-
(2002)
Thromb Res
, vol.105
, pp. 433-439
-
-
Cvirn, G.1
Gallistl, S.2
Koestenberger, M.3
-
20
-
-
0040778249
-
Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin
-
Shen L, Dahlback B, Villoutreix BO. Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin. Biochemistry 2002; 39: 2853-60.
-
(2002)
Biochemistry
, vol.39
, pp. 2853-2860
-
-
Shen, L.1
Dahlback, B.2
Villoutreix, B.O.3
-
21
-
-
0035844272
-
Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C
-
Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567-70.
-
(2001)
J Biol Chem
, vol.276
, pp. 15567-15570
-
-
Rezaie, A.R.1
-
22
-
-
80055107829
-
Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma
-
Brummel-Ziedins KE, Whelihan MF, Rivard GE et al. Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma. J Thromb Haemost 2011; 9: 2262-7.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 2262-2267
-
-
Brummel-Ziedins, K.E.1
Whelihan, M.F.2
Rivard, G.E.3
-
23
-
-
33750058557
-
Peptidomimetic inhibitors for activated protein C: implications for hemophilia management
-
Butenas S, Orfeo T, Kalafatis M et al. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management. J Thromb Haemost 2006; 4: 2411-6.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 2411-2416
-
-
Butenas, S.1
Orfeo, T.2
Kalafatis, M.3
-
24
-
-
0032521665
-
Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function
-
Gal SW, Amontov S, Urvil PT et al. Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function. Eur J Biochem 1998; 252: 553-62.
-
(1998)
Eur J Biochem
, vol.252
, pp. 553-562
-
-
Gal, S.W.1
Amontov, S.2
Urvil, P.T.3
-
25
-
-
64749104065
-
An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor
-
Müller J, Isermann B, Dücker C et al. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol 2009; 16: 442-51.
-
(2009)
Chem Biol
, vol.16
, pp. 442-451
-
-
Müller, J.1
Isermann, B.2
Dücker, C.3
-
26
-
-
84923112064
-
-
An RNAi therapeutic targeting antithrombin increases thrombin generation and hemostasis. XXIV Congress of ISTH, abstr.
-
Sehgal A, Barros S, Qin J. An RNAi therapeutic targeting antithrombin increases thrombin generation and hemostasis. XXIV Congress of ISTH, 2013; abstr.
-
(2013)
-
-
Sehgal, A.1
Barros, S.2
Qin, J.3
-
27
-
-
84923076343
-
-
Expanded therapeutic index of antithrombin silencing and correction of APTT in a haemophilia mouse model. 55th Am Soc of Hematol Meeting, abstr.
-
Barros SA, Carioto M, Hettinger J et al. Expanded therapeutic index of antithrombin silencing and correction of APTT in a haemophilia mouse model. 55th Am Soc of Hematol Meeting, 2013; abstr.
-
(2013)
-
-
Barros, S.A.1
Carioto, M.2
Hettinger, J.3
-
28
-
-
84923112063
-
-
A subcutaneously administered RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in healthy volunteers and patients with hemophilia A or B. 56th ASH Meeting, 93 (abstr).
-
Mant T, Akinc A, Simon A et al. A subcutaneously administered RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in healthy volunteers and patients with hemophilia A or B. 56th ASH Meeting, 2014; 93 (abstr).
-
(2014)
-
-
Mant, T.1
Akinc, A.2
Simon, A.3
-
29
-
-
0025819780
-
Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma
-
Nordfang O, Valentin S, Beck TC et al. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991; 66: 464-7.
-
(1991)
Thromb Haemost
, vol.66
, pp. 464-467
-
-
Nordfang, O.1
Valentin, S.2
Beck, T.C.3
-
30
-
-
33645538085
-
Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP)
-
Liu T, Scallan CD, Broze GJ Jr et al. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76.
-
(2006)
Thromb Haemost
, vol.95
, pp. 68-76
-
-
Liu, T.1
Scallan, C.D.2
Broze Jr, G.J.3
-
31
-
-
38349145384
-
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A
-
Prasad S, Lillicrap D, Labelle A et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 2008; 111: 672-9.
-
(2008)
Blood
, vol.111
, pp. 672-679
-
-
Prasad, S.1
Lillicrap, D.2
Labelle, A.3
-
32
-
-
84892650393
-
Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI)
-
Dockal M, Hartmann R, Fries M et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem 2014; 289: 1732-41.
-
(2014)
J Biol Chem
, vol.289
, pp. 1732-1741
-
-
Dockal, M.1
Hartmann, R.2
Fries, M.3
-
33
-
-
84862499521
-
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model
-
Hilden I, Lauritzen B, Sørensen BB et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119: 5871-8.
-
(2012)
Blood
, vol.119
, pp. 5871-5878
-
-
Hilden, I.1
Lauritzen, B.2
Sørensen, B.B.3
-
34
-
-
79956299608
-
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor
-
Waters EK, Genga RM, Schwartz MC et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011; 117: 5514-22.
-
(2011)
Blood
, vol.117
, pp. 5514-5522
-
-
Waters, E.K.1
Genga, R.M.2
Schwartz, M.C.3
-
35
-
-
84870238164
-
Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia
-
Gissel M, Orfeo T, Foley JH et al. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res 2012; 130: 948-55.
-
(2012)
Thromb Res
, vol.130
, pp. 948-955
-
-
Gissel, M.1
Orfeo, T.2
Foley, J.H.3
-
36
-
-
84883756006
-
Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein
-
Waters EK, Genga RM, Thomson HA et al. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. Thromb Haemost 2013; 11: 1137-45.
-
(2013)
Thromb Haemost
, vol.11
, pp. 1137-1145
-
-
Waters, E.K.1
Genga, R.M.2
Thomson, H.A.3
-
37
-
-
84923087766
-
-
Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499. 54th Am Society of Hematol Meeting, Abstract 1104.
-
Dockal M, Pachlinger R, Hartmann R et al. Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499. 54th Am Society of Hematol Meeting, 2012; Abstract 1104.
-
(2012)
-
-
Dockal, M.1
Pachlinger, R.2
Hartmann, R.3
-
38
-
-
84923093896
-
Treatment of hemophilia A and B with BAX 499, an aptamer based specific inhibitor of TFPI - summary data of a clinical phase 1 trial
-
Wong WY, Bevan D, Sorensen B et al. Treatment of hemophilia A and B with BAX 499, an aptamer based specific inhibitor of TFPI - summary data of a clinical phase 1 trial. Haemophilia 2012; 18: 531.
-
(2012)
Haemophilia
, vol.18
, pp. 531
-
-
Wong, W.Y.1
Bevan, D.2
Sorensen, B.3
-
39
-
-
84857978849
-
Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia
-
Maroney SA, Cooley BC, Ferrel JP et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci USA 2012; 109: 3927-31.
-
(2012)
Proc Natl Acad Sci USA
, vol.109
, pp. 3927-3931
-
-
Maroney, S.A.1
Cooley, B.C.2
Ferrel, J.P.3
-
40
-
-
84923100012
-
-
A TFPI inhibitory half life extended fusion peptide proves efficacy in FVIII knock out mice and marmoset monkeys. 56th ASH Meeting, 1469 (abstr).
-
Dockal M, Hartmann R, Polakowski T et al. A TFPI inhibitory half life extended fusion peptide proves efficacy in FVIII knock out mice and marmoset monkeys. 56th ASH Meeting, 2014; 1469 (abstr).
-
(2014)
-
-
Dockal, M.1
Hartmann, R.2
Polakowski, T.3
-
42
-
-
39649106357
-
Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis
-
Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu Rev Med 2008; 59: 29-41.
-
(2008)
Annu Rev Med
, vol.59
, pp. 29-41
-
-
Hedner, U.1
Ezban, M.2
-
43
-
-
0023720558
-
A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo
-
Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69: 491-7.
-
(1988)
Br J Haematol
, vol.69
, pp. 491-497
-
-
Giles, A.R.1
Mann, K.G.2
Nesheim, M.E.3
-
44
-
-
0036908074
-
A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo
-
Himmelspach M, Richter G, Muhr E et al. A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo. Thromb Haemost 2002; 88: 1003-11.
-
(2002)
Thromb Haemost
, vol.88
, pp. 1003-1011
-
-
Himmelspach, M.1
Richter, G.2
Muhr, E.3
-
45
-
-
0346874351
-
A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone
-
Tomokiyo K, Nakatomi Y, Araki T et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 2003; 85: 290-9.
-
(2003)
Vox Sang
, vol.85
, pp. 290-299
-
-
Tomokiyo, K.1
Nakatomi, Y.2
Araki, T.3
-
46
-
-
0028811109
-
Procoagulant activity of reversibly acylated human factor Xa
-
Wolf DL, Lin PH, Hollenbach S et al. Procoagulant activity of reversibly acylated human factor Xa. Blood 1995; 86: 4153-7.
-
(1995)
Blood
, vol.86
, pp. 4153-4157
-
-
Wolf, D.L.1
Lin, P.H.2
Hollenbach, S.3
-
47
-
-
29244450161
-
Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas
-
Louvain-Quintard VB, Bianchini EP, Calmel-Tareau C et al. Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas. J Biol Chem 2005; 280: 41352-9.
-
(2005)
J Biol Chem
, vol.280
, pp. 41352-41359
-
-
Louvain-Quintard, V.B.1
Bianchini, E.P.2
Calmel-Tareau, C.3
-
48
-
-
84864111891
-
Bioengineered factor Xa as a potential new strategy for hemophilia therapy
-
Camire RM. Bioengineered factor Xa as a potential new strategy for hemophilia therapy. Expert Rev Hematol 2012; 5: 121-3.
-
(2012)
Expert Rev Hematol
, vol.5
, pp. 121-123
-
-
Camire, R.M.1
-
49
-
-
78650988916
-
Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
-
Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 2011; 117: 290-8.
-
(2011)
Blood
, vol.117
, pp. 290-298
-
-
Bunce, M.W.1
Toso, R.2
Camire, R.M.3
-
50
-
-
80755125572
-
A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia
-
Ivanciu L, Toso R, Margaritis P et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol 2011; 29: 1028-33.
-
(2011)
Nat Biotechnol
, vol.29
, pp. 1028-1033
-
-
Ivanciu, L.1
Toso, R.2
Margaritis, P.3
-
51
-
-
84355162288
-
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - phase I trial
-
Shirahata A, Fukutake K, Mimaya J et al. Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - phase I trial. Haemophilia 2012; 18: 94-101.
-
(2012)
Haemophilia
, vol.18
, pp. 94-101
-
-
Shirahata, A.1
Fukutake, K.2
Mimaya, J.3
-
52
-
-
84874092003
-
Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors - phase I trial: 2nd report
-
Shirahata A, Fukutake K, Mimaya J et al. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors - phase I trial: 2nd report. Haemophilia 2013; 19: 330-7.
-
(2013)
Haemophilia
, vol.19
, pp. 330-337
-
-
Shirahata, A.1
Fukutake, K.2
Mimaya, J.3
-
53
-
-
84886639305
-
A phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics
-
Shirahata A, Fukutake K, Takamatsu J et al. A phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia 2013; 19: 853-60.
-
(2013)
Haemophilia
, vol.19
, pp. 853-860
-
-
Shirahata, A.1
Fukutake, K.2
Takamatsu, J.3
-
54
-
-
0036707993
-
Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C
-
Gale AJ, Xu X, Pellequer JL et al. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci 2002; 11: 2091-101.
-
(2002)
Protein Sci
, vol.11
, pp. 2091-2101
-
-
Gale, A.J.1
Xu, X.2
Pellequer, J.L.3
-
55
-
-
84896802437
-
Improved hemostasis in hemophilia mice by means of an engineered FVa mutant
-
von Drygalski A, Cramer T, Bhat V et al. Improved hemostasis in hemophilia mice by means of an engineered FVa mutant. J Thromb Haemost 2014; 12: 363-72.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 363-372
-
-
von Drygalski, A.1
Cramer, T.2
Bhat, V.3
-
56
-
-
85116184768
-
-
superfva and recombinant human FVIIa in vivo suggests a novel bypassing strategy for hemophilia patients with inhibitors. 56th ASH Meeting, 691 (abstr).
-
superfva and recombinant human FVIIa in vivo suggests a novel bypassing strategy for hemophilia patients with inhibitors. 56th ASH Meeting, 2014; 691 (abstr).
-
(2014)
-
-
Bhat, V.1
von Drygalski, A.2
Gale, A.3
-
57
-
-
84855832171
-
Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice
-
Milanov P, Ivanciu L, Abriss D et al. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood 2012; 119: 602-11.
-
(2012)
Blood
, vol.119
, pp. 602-611
-
-
Milanov, P.1
Ivanciu, L.2
Abriss, D.3
-
58
-
-
34948831582
-
A potent erythropoietin-mimicking human antibody interacts through a novel binding site
-
Liu Z, Stoll VS, Devries PJ et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 2007; 110: 2408-13.
-
(2007)
Blood
, vol.110
, pp. 2408-2413
-
-
Liu, Z.1
Stoll, V.S.2
Devries, P.J.3
-
59
-
-
84860577150
-
A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control
-
Bhaskar V, Goldfine ID, Bedinger DH et al. A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 2012; 61: 1263-71.
-
(2012)
Diabetes
, vol.61
, pp. 1263-1271
-
-
Bhaskar, V.1
Goldfine, I.D.2
Bedinger, D.H.3
-
60
-
-
0037186916
-
The prevalence of proteolytic antibodies against factor VIII in hemophilia A
-
Lacroix-Desmazes S, Bayry J, Misra N et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002; 346: 662-7.
-
(2002)
N Engl J Med
, vol.346
, pp. 662-667
-
-
Lacroix-Desmazes, S.1
Bayry, J.2
Misra, N.3
-
61
-
-
0041880705
-
Autoantibodies to factor VIII with catalytic activity
-
Bayry J, Lacroix-Desmazes S, Pashov A et al. Autoantibodies to factor VIII with catalytic activity. Autoimmun Rev 2003; 2: 30-5.
-
(2003)
Autoimmun Rev
, vol.2
, pp. 30-35
-
-
Bayry, J.1
Lacroix-Desmazes, S.2
Pashov, A.3
-
62
-
-
4644358187
-
An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex
-
Kerschbaumer RJ, Riedrich K, Kral M et al. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex. J Biol Chem 2004; 279: 40445-50.
-
(2004)
J Biol Chem
, vol.279
, pp. 40445-40450
-
-
Kerschbaumer, R.J.1
Riedrich, K.2
Kral, M.3
-
63
-
-
84870302675
-
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
-
Kitazawa T, Igawa T, Sampei Z et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18: 1570-4.
-
(2012)
Nat Med
, vol.18
, pp. 1570-1574
-
-
Kitazawa, T.1
Igawa, T.2
Sampei, Z.3
-
64
-
-
84911438456
-
The anti-factor IXa/X bispecific antibody ACE910 prevents spontaneous joint bleeds in a long-term primate model of acquired hemophilia A
-
Muto A, Yoshihashi K, Takeda M et al. The anti-factor IXa/X bispecific antibody ACE910 prevents spontaneous joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124: 3165-71.
-
(2014)
Blood
, vol.124
, pp. 3165-3171
-
-
Muto, A.1
Yoshihashi, K.2
Takeda, M.3
-
65
-
-
84893537691
-
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
-
Muto A, Yoshihashi K, Takeda M et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 2013; 12: 206-13.
-
(2013)
J Thromb Haemost
, vol.12
, pp. 206-213
-
-
Muto, A.1
Yoshihashi, K.2
Takeda, M.3
-
66
-
-
84923072168
-
The safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, demonstrated in healthy adults
-
Shima M, Uchida N, Sanbe T et al. The safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, demonstrated in healthy adults. Haemophilia 2014; 20: 76.
-
(2014)
Haemophilia
, vol.20
, pp. 76
-
-
Shima, M.1
Uchida, N.2
Sanbe, T.3
-
67
-
-
84923076342
-
-
Safety and prophylactic efficacy profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, in Japanese hemophilia A patients both without and with FVIII Inhibitors: first-in-patient phase 1 study. 56th ASH Meeting, 691 (abstr).
-
Shima M, Hanabusa H, Taki M et al. Safety and prophylactic efficacy profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, in Japanese hemophilia A patients both without and with FVIII Inhibitors: first-in-patient phase 1 study. 56th ASH Meeting, 2014; 691 (abstr).
-
(2014)
-
-
Shima, M.1
Hanabusa, H.2
Taki, M.3
-
68
-
-
84893573623
-
FXIII - mechanisms of action in the treatment of hemophilia A
-
Rea CJ, Foley JH, Okaisabor O et al. FXIII - mechanisms of action in the treatment of hemophilia A. J Thromb Haemost 2014; 12: 159-68.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 159-168
-
-
Rea, C.J.1
Foley, J.H.2
Okaisabor, O.3
-
69
-
-
79952065857
-
Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A
-
Rea CJ, Foley JH, Ingerslev J et al. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. J Thromb Haemost 2011; 9: 510-6.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 510-516
-
-
Rea, C.J.1
Foley, J.H.2
Ingerslev, J.3
-
70
-
-
0041965943
-
Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A
-
Hrachovinová I, Cambien B, Hafezi-Moghadam A et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003; 9: 1020-5.
-
(2003)
Nat Med
, vol.9
, pp. 1020-1025
-
-
Hrachovinová, I.1
Cambien, B.2
Hafezi-Moghadam, A.3
-
71
-
-
0035997219
-
Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system
-
Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med (Berl) 2002; 80: 367-76.
-
(2002)
J Mol Med (Berl)
, vol.80
, pp. 367-376
-
-
Keeling, K.M.1
Bedwell, D.M.2
-
72
-
-
77956311645
-
Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124)
-
Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010; 25: 1158-64.
-
(2010)
J Child Neurol
, vol.25
, pp. 1158-1164
-
-
Finkel, R.S.1
-
73
-
-
27644488290
-
Aminoglycoside suppression of nonsense mutations in severe hemophilia
-
James PD, Raut S, Rivard GE et al. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005; 106: 3043-8.
-
(2005)
Blood
, vol.106
, pp. 3043-3048
-
-
James, P.D.1
Raut, S.2
Rivard, G.E.3
-
74
-
-
78649462808
-
Nonsense suppression approaches in treating hemophilia
-
512 (Abstract)
-
Liu Y-L, Margaritis P, Khazi F et al. Nonsense suppression approaches in treating hemophilia. Blood 2008; 112: 512 (Abstract)
-
(2008)
Blood
, vol.112
-
-
Liu, Y.-L.1
Margaritis, P.2
Khazi, F.3
-
75
-
-
0033525169
-
A perfect message: RNA surveillance and nonsense-mediated decay
-
Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay. Cell 1999; 96: 307-10.
-
(1999)
Cell
, vol.96
, pp. 307-310
-
-
Hentze, M.W.1
Kulozik, A.E.2
-
76
-
-
0033846632
-
Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro
-
Ghosh K, Shetty S, Pathare A et al. Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro. Acta Haematol 2000; 103: 67-72.
-
(2000)
Acta Haematol
, vol.103
, pp. 67-72
-
-
Ghosh, K.1
Shetty, S.2
Pathare, A.3
-
77
-
-
1042304227
-
Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors
-
Ghosh K, Shetty S, Jijina F et al. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia 2004; 10: 58-62.
-
(2004)
Haemophilia
, vol.10
, pp. 58-62
-
-
Ghosh, K.1
Shetty, S.2
Jijina, F.3
-
78
-
-
84923092537
-
Nanobody-based TAFIa stabilization stabilizes hemophilia A clots and reduces the bleeding tendency in mice
-
Hendrickx M, Declerck P, Mosnier L. Nanobody-based TAFIa stabilization stabilizes hemophilia A clots and reduces the bleeding tendency in mice. Haemophilia 2014; 20: 79.
-
(2014)
Haemophilia
, vol.20
, pp. 79
-
-
Hendrickx, M.1
Declerck, P.2
Mosnier, L.3
-
79
-
-
84923087765
-
-
Prevention of premature fibrinolysis and reduction of bleeding in vivo in hemophilia with inhibitors by a stabilized TAFI variant. 56th ASH Meeting, 694 (abstr).
-
Hendrickx M, Bhat V, Gills A et al. Prevention of premature fibrinolysis and reduction of bleeding in vivo in hemophilia with inhibitors by a stabilized TAFI variant. 56th ASH Meeting, 2014; 694 (abstr).
-
(2014)
-
-
Hendrickx, M.1
Bhat, V.2
Gills, A.3
|